Renaissance BioScience Corp., a global leader in yeast bioengineering, has announced the appointment of Dr. James Tansey to its Board of Directors. Dr. Tansey brings extensive experience in life sciences, technology commercialization, fundraising, and corporate governance, which will support the company's growth and commercialization of its innovative biotechnology platforms.
Dr. Tansey is a professor at the University of British Columbia's Sauder School of Business and previously served on the faculty at Oxford University's Saïd Business School. He is a founding team member of Gemina Labs, where he assists with fundraising, business development, and shareholder strategy. Additionally, he serves on the boards of dynaCERT Inc. and Vanadium Resources Ltd., and is a Senior Advisor to InBC, British Columbia's $500 million strategic investment fund.
Maurice Boucher, Renaissance Co-Founder and Executive Chairman, expressed enthusiasm about the appointment, stating that Dr. Tansey's entrepreneurial, strategic, and governance experience, along with his focus on impact investing and environmental sustainability, aligns well with Renaissance's technology platforms. Boucher emphasized that Dr. Tansey's expertise will be valuable as the company continues developing and globally commercializing its biotechnology solutions.
Dr. Tansey commented on his new role, noting that Renaissance has developed an impressive portfolio of innovative technologies with significant commercial potential across agriculture, industrial biotechnology, and animal and human health. He looks forward to working with the Board and management to execute the company's growth strategy and create long-term value.
Dr. John Husnik, Renaissance Co-Founder, Director, and CSO, also welcomed Dr. Tansey, highlighting his experience in building companies, securing investment, and moving innovative technologies toward commercialization, which will complement the company's scientific expertise.
Renaissance BioScience Corp., based in Vancouver, Canada, is a global-leading yeast bioengineering company that develops market-ready, functional microorganisms to address environmental and industrial challenges in agriculture, food, nutrition, and animal and human health. The company's technology platforms include yeast-produced RNA and yeast-derived virus-like particles (VLPs), with initial applications in crop protection and future applications in animal and human health.
The appointment of Dr. Tansey marks a strategic move for Renaissance as it seeks to accelerate the commercialization of its biotechnology platforms and expand its impact in sustainable agriculture and health sectors. His experience in impact investing and technology commercialization is expected to help the company attract investment and navigate the path to market for its innovative solutions.
